抄録
Purpose: We investigated the effectiveness of monotherapy with Cosopt® in reducing intraocular pressure (IOP) in patients who could not tolerate the side effects of prostaglandin (PG) formulations or who preferred to avoid combination therapy.
Subjects and methods: The subjects were patients with broadly defined primary open-angle glaucoma or ocular hypertension who had been treated with PG formulations combined with brinzolamide. Mean IOP was compared before and after treatment was changed to monotherapy with Cosopt®.
Results: Overall, switching to monotherapy with Cosopt® significantly reduced IOP (p=0.038), particularly in the group of patients who had been treated with unoprostone combined with brinzolamide (p=0.005). However, IOP did not change in the subjects who had received PG analogs with the suffix "-prost" combined with brinzolamide.
Conclusions: Our results show that Cosopt® is effective in reducing IOP, and that it can be considered as a treatment option for patients with glaucoma who cannot tolerate the side effects of PG formulations or who are unresponsive to PG.
